

Supplemental Information

Shaver et al, Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury

Lung Transplant Outcomes Group

University of Pennsylvania (Coordinating site):

Jason Christie, MD, MS (PI), Maria M. Crespo, MD, Steven M. Kawut, MD, MS, Alberto Pocchetino, MD, Y. Joseph Woo, MD, Ejigayehu Demissie, MSN, Robert M. Kotloff, MD, Vivek N. Ahya, MD, James Lee, MD, MS, Denis Hadjiliadis, MD, MHS, Melanie Rushefski, BS, Richard Aplenc, MD, Clifford Deutschman, MD, MS, Benjamin Kohl, MD, Edward Cantu, MD, Joshua M. Diamond, MD, MS, Rupal J. Shah, MD, Laurel Kalman, Michelle Oyster

Columbia University:

David Lederer, MD, MS (PI), Selim Arcasoy, MD, Joshua Sonett, MD, Jessie Wilt, MD, Frank D'Ovidio, MD, Lori Shah, MD, Hilary Robbins, MD, Matthew Bacchetta, MD, Nilani Ravichandran, NP, Genevieve Reilly, NP, Jeffrey Okun, MD, Debbie Rybak, BA, Michael Koeckert, BA, Robert Sorabella, BA, Nisha Ann Philip, MBBS, Nadine Al-Naamani, MD, Matthew LaVelle, BS, Megan Larkin, MPH, Shefali Sanyal, BS

Vanderbilt University:

Lorraine Ware, MD (PI), Aaron Milstone, MD (PI), Jean Barnes, RN, Stephanie Logan, RN, Carla Ramsey, RN, Thelma Walden, Shaquita Claybrooks, RN

Stanford University:

Ann Weinacker, MD (PI), Susan Spencer Jacobs, MSN, Val Scott, MSN, Tal Alfasi, MS

University of Alabama, Birmingham:

Keith Wille, MD (PI), Necole Harris, RN

Johns Hopkins University:

Jonathan Orens, MD (PI), Pali D. Shah, MD, Ashish Shah, MD, Christian Merlo, MD, MPH, Matthew Pipeling, MD, Reda Girgis, MD, Karen Oakjones, RN, April Thurman

University of Michigan:

Vibha Lama, MD, MS (PI), Fernando Martinez, MD, MS, Emily Galopin, Douglas R. Armstrong R.N, MS, Mary Maliarik, BS

Duke University:

Scott M. Palmer, MD, MHS (PI), Laurie Snyder, MD, David Zaas, MD, MBA, R. Duane Davis, MD, Ashley Finlen-Copeland, MSW, Jessica Martissa, William A. Davis

University of Chicago:

Sangeeta Bhorade, MD (PI), Mark Lockwood, RN, MSN

University of Pittsburgh:

John McDyer, MD, Joseph Pilewski, MD, Christian Bermudez, MD, Kathleen Hanze

Indiana University:

David S. Wilkes, MD, Chadi Hage, MD, David Wilson Roe, MD, Thomas Wozniak, MD,
Ronda L. McNamee, RN, Kim A. Fox, RN, Danyel F. Gooch, RN, Tonya Isaacs, RN


University of California San Francisco:

Rupal J. Shah, MD, MS, Jonathan P. Singer, MD, MS, Jasleen Kukreja, MD, MPH

Supplemental Table 1. Patient characteristics stratified by cell-free hemoglobin (CFH) level.

Characteristic	CFH <30mg/dL (n=57)	CFH ≥30mg/dL (n=58)	P value
Age	58 (52, 61)	55 (47, 61)	0.18
Male	28 (49%)	36 (62%)	0.16
European Descent	51 (89%)	49 (84%)	0.85
Diagnosis			0.52
COPD	24 (42%)	22 (38%)	
CF	1 (0%)	0 (0%)	
ILD	32 (56%)	36 (62%)	
Other	0 (0%)	0 (0%)	
Bilateral lung transplant	33 (58%)	38 (66%)	0.40
Ischemic time (min)	238 (197, 262)	234 (204, 268)	0.74
Cardiopulmonary bypass	17 (30%)	28 (48%)	0.04
mPAP	23.0 (19.8, 36.2)	29.3 (22.9, 36.1)	0.07
pRBC transfusion (mL)	500 (250, 1200)	500 (250, 1000)	0.79
Body mass index	25.9 (23.2, 29.1)	26.8 (23.7, 29.1)	0.44
Donor smoke exposure	31 (54%)	26 (45%)	0.28
Reperfusion FIO ₂	0.58 (0.33, 0.86)	0.53 (0.29, 0.82)	0.46
Grade 3 PGD at 72h	13 (23%)	26 (45%)	0.01
90-day mortality	5 (9%)	8 (14%)	0.40
1-year mortality	10 (18%)	11 (19%)	0.84

Data are shown as n (%) or median (25th percentile, 75th percentile). Comparisons were made by Mann Whitney U test or Chi-squared test as appropriate. Cardiopulmonary bypass is limited to intra-operative use of bypass. COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; FIO₂, fraction of inspired oxygen; ILD, interstitial lung disease; mPAP, mean pulmonary artery pressure; pRBC, packed red blood cell



Supplemental Figure 1. Plasma cell-free hemoglobin (CFH) levels do not differ by recipient diagnosis. (A) Pre-operative CFH levels (B) Post-operative CFH levels at 6 hrs after lung transplantation (C) Post-operative CFH levels at 24 hrs after lung transplantation. n=46 for COPD, n=68 for ILD.